We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
April 4, 2023,InnoCare Pharma announced today that the first subject has been dosed in clinical trial of the Company’s novel targeted protein degrader ICP-490 in China.